Gene Expression Biomarkers for LUAD Subtype Prognosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic and therapeutic approaches for lung adenocarcinoma (LUAD) are hindered by morphological and molecular heterogeneity, making it challenging to predict clinical outcomes and effectively target treatments.
Innovation Solution
Utilizing a set of differentially regulated genes, including CLIP1, AVEN, SRPRA, PUS1, MYO1E, KIF26B, FOSL2, MATR3, RPS6KA5, TOR1AIP1, MTX3, UTRN, TMX4, and MCCC1, as biomarkers to predict clinical outcomes and administer targeted therapies based on molecular subtypes like PI, TRU, and PP.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If molecular profiling efforts catalog a diversity of somatic DNA alterations in LUAD, then the understanding of molecular heterogeneity is improved, but the ability to predict clinical outcomes remains challenging
Solution Approach 1:
The patent segments the complex molecular profile of LUAD into distinct molecular subtypes (LEPID, INFLAMMATORY, NEURAL, GLIOBLASTOMA-like) based on gene expression patterns. This segmentation transforms the continuous molecular heterogeneity into discrete, clinically actionable categories that can be used to predict survival outcomes and guide treatment decisions.
Solution Approach 2:
The patent changes the parameters used for molecular characterization from traditional somatic DNA alterations to gene expression-based molecular subtypes. By using gene expression profiles and calculating molecular subtype scores, the patent creates new predictive parameters that directly correlate with clinical outcomes such as overall survival and metastasis-free survival.
2Adaptability or versatility
If targeted therapies are developed based on somatic DNA alterations, then treatment options are expanded, but many LUAD tumors still lack indicated molecular alterations for targeted therapy
Solution Approach 1:
The patent develops molecular subtype classification that has universal applicability across all LUAD tumors regardless of specific driver mutations. The molecular subtype scores can be calculated for any LUAD tumor based on gene expression profiles, providing a universal framework for treatment selection that works even when traditional targeted therapy indications are absent.
Solution Approach 2:
The patent introduces molecular subtype classification as an intermediary layer between tumor molecular characteristics and treatment selection. Instead of directly matching tumors to targeted therapies based on specific mutations, the molecular subtype score serves as a mediator that guides treatment decisions, including immunotherapy selection, for tumors without traditional targeted therapy indications.
3Measurement precision
If morphological and molecular heterogeneity within and among tumors is acknowledged, then diagnostic accuracy is improved, but the complexity of diagnosis and treatment increases
Solution Approach 1:
The patent applies local quality by assigning different molecular subtype characteristics to different tumors based on their specific gene expression profiles. Each tumor is evaluated individually for its molecular subtype score, allowing diagnostic accuracy to be improved through personalized molecular characterization without requiring complex universal diagnostic systems.
Solution Approach 2:
The patent replaces complex pathological and molecular analysis with a computational approach that calculates molecular subtype scores from gene expression data. This substitution of mechanical/pathological examination with computational scoring simplifies the diagnostic process while maintaining or improving accuracy through objective, quantifiable molecular subtype classification.
Data Source
AI summary
This application relates generally to lung cancer-related biomarkers, such as aggressive lung cancer-related molecules, which can be used to predict clinical outcomes, such as patient overall survival and/or metastasis-free survival, and methods of using the same to diagnose, prognose, monitor, and treat lung cancer, such as lung adenocarcinoma, in a subject